167 related articles for article (PubMed ID: 19661550)
1. Prevention of tuberculosis in patients taking tumor necrosis factor-alpha blockers.
Bellofiore B; Matarese A; Balato N; Gaudiello F; Scarpa R; Atteno M; Bocchino M; Sanduzzi A
J Rheumatol Suppl; 2009 Aug; 83():76-7. PubMed ID: 19661550
[TBL] [Abstract][Full Text] [Related]
2. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
3. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
4. [The clinical application of quantiferon TB-2G: its usefulness and limitations].
Sato S; Nagai H
Kekkaku; 2011 Feb; 86(2):101-12. PubMed ID: 21404654
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Elkayam O; Balbir-Gurman A; Lidgi M; Rahav G; Weiler-Ravel D
Harefuah; 2007 Mar; 146(3):235-7, 244. PubMed ID: 17460934
[TBL] [Abstract][Full Text] [Related]
6. Tuberculosis infections and tumor necrosis factor alpha antagonists.
Gan J; Manadan AM; Sequiera W; Block JA
Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
[TBL] [Abstract][Full Text] [Related]
7. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
[TBL] [Abstract][Full Text] [Related]
8. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
Keane J
Rheumatology (Oxford); 2005 Jun; 44(6):714-20. PubMed ID: 15741198
[TBL] [Abstract][Full Text] [Related]
9. [Tuberculosis associated with anti-TNF therapy].
Takeno M; Murakami S; Ishigatsubo Y
Nihon Rinsho; 2007 Jul; 65(7):1308-13. PubMed ID: 17642248
[TBL] [Abstract][Full Text] [Related]
10. [Update of the guidelines of the Israeli Association of Rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Balbir-Gurman A; Lidgi M; Elkayam O
Harefuah; 2014 Jun; 153(6):359-61, 366. PubMed ID: 25095612
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
[TBL] [Abstract][Full Text] [Related]
12. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis screening in prescribers of anti-tumor necrosis factor therapy in the European Union.
Smith MY; Attig B; McNamee L; Eagle T
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1168-73. PubMed ID: 22794309
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
16. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis.
Harris J; Hope JC; Keane J
J Infect Dis; 2008 Dec; 198(12):1842-50. PubMed ID: 18954258
[TBL] [Abstract][Full Text] [Related]
18. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
Gómez-Reino JJ; Carmona L; Angel Descalzo M;
Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor blockers and reactivation of latent tuberculosis.
Keane J
Clin Infect Dis; 2004 Aug; 39(3):300-2. PubMed ID: 15306994
[No Abstract] [Full Text] [Related]
20. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]